Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
- PMID: 29190166
- DOI: 10.1080/17460441.2018.1410135
Non-alcoholic fatty liver disease (NAFLD) models in drug discovery
Abstract
The progressive disease spectrum of non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis (NASH), is a rapidly emerging public health crisis with no approved therapy. The diversity of various therapies under development highlights the lack of consensus around the most effective target, underscoring the need for better translatable preclinical models to study the complex progressive disease and effective therapies. Areas covered: This article reviews published literature of various mouse models of NASH used in preclinical studies, as well as complex organotypic in vitro and ex vivo liver models being developed. It discusses translational challenges associated with both kinds of models, and describes some of the studies that validate their application in NAFLD. Expert opinion: Animal models offer advantages of understanding drug distribution and effects in a whole body context, but are limited by important species differences. Human organotypic in vitro and ex vivo models with physiological relevance and translatability need to be used in a tiered manner with simpler screens. Leveraging newer technologies, like metabolomics, proteomics, and transcriptomics, and the future development of validated disease biomarkers will allow us to fully utilize the value of these models to understand disease and evaluate novel drugs in isolation or combination.
Keywords: Non-alcoholic fatty liver disease (NAFLD); fibrosis; hepatic stellate cell; hepatocyte; inflammation; non-alcoholic steatohepatitis (NASH); organotypic; preclinical; steatosis.
Similar articles
-
Mouse models of nonalcoholic steatohepatitis in preclinical drug development.Drug Discov Today. 2017 Nov;22(11):1707-1718. doi: 10.1016/j.drudis.2017.06.007. Epub 2017 Jul 4. Drug Discov Today. 2017. PMID: 28687459 Review.
-
Preclinical models of non-alcoholic fatty liver disease.J Hepatol. 2018 Feb;68(2):230-237. doi: 10.1016/j.jhep.2017.10.031. Epub 2017 Nov 9. J Hepatol. 2018. PMID: 29128391 Free PMC article. Review.
-
How effective are nonalcoholic fatty liver disease models for drug discovery?Expert Opin Drug Discov. 2020 Nov;15(11):1237-1240. doi: 10.1080/17460441.2020.1776258. Epub 2020 Jun 11. Expert Opin Drug Discov. 2020. PMID: 32524859
-
Promising therapies for treatment of nonalcoholic steatohepatitis.Expert Opin Emerg Drugs. 2016 Sep;21(3):343-57. doi: 10.1080/14728214.2016.1220533. Epub 2016 Aug 28. Expert Opin Emerg Drugs. 2016. PMID: 27501374 Free PMC article. Review.
-
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.J Transl Med. 2015 Jun 16;13:193. doi: 10.1186/s12967-015-0552-7. J Transl Med. 2015. PMID: 26077675 Free PMC article.
Cited by
-
Characteristics of gut microbiota in patients with metabolic associated fatty liver disease.Sci Rep. 2023 Jun 20;13(1):9988. doi: 10.1038/s41598-023-37163-4. Sci Rep. 2023. PMID: 37340081 Free PMC article.
-
Engineering Modular 3D Liver Culture Microenvironments In Vitro to Parse the Interplay between Biophysical and Biochemical Microenvironment Cues on Hepatic Phenotypes.Adv Nanobiomed Res. 2022 Jan;2(1):2100049. doi: 10.1002/anbr.202100049. Epub 2021 Nov 19. Adv Nanobiomed Res. 2022. PMID: 35872804 Free PMC article.
-
Akkermansia muciniphila Enhances Egg Quality and the Lipid Profile of Egg Yolk by Improving Lipid Metabolism.Front Microbiol. 2022 Jul 19;13:927245. doi: 10.3389/fmicb.2022.927245. eCollection 2022. Front Microbiol. 2022. PMID: 35928144 Free PMC article.
-
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.JHEP Rep. 2020 Nov 20;3(2):100217. doi: 10.1016/j.jhepr.2020.100217. eCollection 2021 Apr. JHEP Rep. 2020. PMID: 33490936 Free PMC article.
-
Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.Adv Exp Med Biol. 2022;1372:157-168. doi: 10.1007/978-981-19-0394-6_11. Adv Exp Med Biol. 2022. PMID: 35503180
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical